Trial Profile
ABCB1/P-glycoprotein Expression as Biologic Stratification Factor for Patients With Non Metastatic Osteosarcoma - Prospective Study (ISG/OS-2).
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Oct 2023
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Doxorubicin (Primary) ; Ifosfamide (Primary) ; Methotrexate (Primary) ; Mifamurtide (Primary)
- Indications Osteosarcoma
- Focus Therapeutic Use
- Acronyms ISG/OS-2
- 03 Oct 2023 Planned End Date changed from 30 Oct 2023 to 30 Dec 2023.
- 03 Oct 2023 Planned primary completion date changed from 30 Oct 2023 to 30 Dec 2023.
- 16 Sep 2022 Planned End Date changed from 30 Oct 2021 to 30 Oct 2023.